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Background: While HIV, AIDS and atypical Mycobacterium infections are closely linked, the use of Integrase-Inhibitor
based cART, notably raltegravir-based regimens is more widespread. RAL should be double-dosed to 800 mg semi-daily
in situation of rifampicin co-medication, because RAL is more rapidly metabolized due to rifampicin-induced
Uridine-5’-diphosph- gluronosyl-transferase (UGT1A1). Recently, it was speculated that chewed RAL might lead to
increased absorption, which might compensate the inductive effect of rifampicin-rapid metabolized RAL, as part
of cost-saving effects in countries with high-tuberculosis prevalence and less economic power.
Methods: We report measurement of raltegravir pharmacokinetics in a 34-year AIDS-patient suffering from
disseminated Mycobacterium avium infection with necessity of parenteral rifampicin treatment. RAL levels were
measured with HPLC (internal standard: carbamazepine, LLQ 11 ng/ml, validation with Valistat 2.0 program
(Arvecon, Germany)). For statistical analysis, a two-sided Wilcoxon signed rank test for paired samples was used.
Results: High intra-personal variability in raltegravir serum levels was seen. Comparable Cmax concentrations were
found for 800 mg chewed and swallowed RAL, as well as for 400 mg chewed and swallowed RAL. While Cmax
seems to be more dependent from overall RAL dosing than from swallowed or chewed tablets, increased AUC12
is clearly linked to higher RAL dosages per administration. Anyway, chewed raltegravir showed a rapid decrease
in serum levels.
Conclusions: We found no evidence that chewed 400 mg semi-daily raltegravir in rifampicin co-medication leads
to optimized pharmacokinetics. There is need for more data from randomized trials for further recommendations.
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While Human Immunodeficiency Virus (HIV), Aquired
Immunodeficiency Syndrome (AIDS) and atypical Myco-
bacteriosis infections are closely linked, the use of Inte-
grase-Inhibitor (INI) based antiretroviral regiments (ART),
notably raltegravir (RAL)-based regiments is more wide-
spread during HAART era. Raltegravir’s benefit is the favor-
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unless otherwise stated.events in HIV- patients [1]. Rifampicin is known to be
active against atypical Mycobacterial infections, including
Mycobacterium avium infections [2]. [3] Nevertheless, RAL
is more rapidly metabolized in case of rifampicin co-ad-
ministration due to rifampicin-induced Uridine-5’-diphosph-
gluronosyl-transferase (UGT1A1) [1,4]. Therefore, it is
recommended to double-dose RAL to 800 mg semi-daily
(BID) in case of Rifampicin-use, which causes high add-
itional costs in these patients [4]. Recently, there has been
conflicting data, which suggests using a standard-dose of
400 mg RAL BID, taken chewed as part of an ART, might,
in the event of Rifampicin co-administration, lead to
higher drug absorption and lower drug intersubject phar-
macokinetic variability [5,6]. As reported recently, it wasl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Pharmacokinetic data of Raltegravir after
administration of different dosages of raltegravir by
chewing or swallowing the drug in a patient with AIDS
and MAI infection









C0h 66 <45 439 47
C1 h 884 865 511 676
C2 h 904 930 781 660
C4 h 699 207 1055 1147
C8 h 71 173 1032 723
C12 h 62 94 885 372
AUC0–4 2972 2489 2957 2837
AUC12 4778 3783 10965 8767
Difference AUC12
(ng/ml); median; min; max
−3,5;-102;492 215;-165;513
(p-value) (p-value 0,84) (p-value 0,22)
Raltegravir serum levels
Figure 1 Pharmacokinetic data of raltegravir after
administration of different dosages (400 mg or 800 mg, BD;
either chewed or swallowed).
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absorption, which might thus compensate the inductive
effect of rapid metabolized RAL due to rifampicin and
therefore have cost-saving effects in countries with
high-tuberculosis prevalence and less economic power
[5]. Despite that aspect, some data for high inter- and
intra-personal variability in pharmacokinetics were reported
for HIV-patients in general [7]. Lack of sufficient RAL
levels were not clearly associated with virological failure of
antiretroviral therapy, but that there might be some influ-
ences of overall plasma exposure of the drug [7,8]. There-
fore, conflicting data in differential RAL dosages play a
major role in decisions on clinical HIV-patient care and
overall antiretroviral therapy success.
Clinical objectives
We report our experience with a recent admission of a
34-year-old Caucasian male HIV-patient, who was diag-
nosed as being HIV/HBV-co-infected 5 years prior to actual
presentation. CDC Stage was C3, WHO stage IV due to
thrush esophagitis and systemic cytomegalovirus reactiva-
tion. CD4-nadir = 8 cells/μl, he was known to belong to the
risk group of men having sex with men.
4 months before current presentation at our center, the
patient was diagnosed with mycobacterium avium infec-
tion in a lymph node biopsy whilst having fever, weight
loss and general lymphadenopathy in a peripheral hospital.
Antiretroviral therapy with co-formulated Tenofovir diso-
proxil fumarate and Emtricitabine (TVD) in combination
with integrase-inhibitor RAL was initiated. Oral anti-
microbial chemotherapy with rifabutin, ethambutol and
clarithromycin was started without delay. The patient was
discharged from the peripheral hospital. Subsequently,
persistent fever and weight loss appeared within the first
months.
The clinical situation worsened despite medical therapy.
He was admitted to our emergency department with shock
and severe hypoglycemia 4 months after initiation of the
first antimycobacterial treatment. The marasmic patient
(body mass index of 15), suffered from 5 liters of watery
diarrhea per day, severe hypoalbuminemia (albumin 1,4
g/dl), protein deficiency (serum protein 4,4 g/dl), and iron
deficiency anemia (hemoglobin 7,0 g/dl). Subsequently,
mycobacterium avium was diagnosed by microscopy and
culture in samples of pleural effusion, stool, sigmoid biopsy
and peripheral blood. No other microorganisms could be
identified in blood culture diagnostics. Due to the lack
of intestinal absorption, antimicrobial chemotherapy was
escalated to parenteral rifampicin (600 mg once daily),
ethambutol (400 mg three times daily), clarithromycin
(500 mg semi-daily) and amikacin (750 mg once daily).
Before adjusting ART to the recommended dose of
800 mg RAL BID (adult formulation) in combination
with Tenfovir disoproxil fumarate co-formulated withEmtricitabine, subsequent pharmacokinetic studies were
performed after informed consent of the patient. In doing
so, RAL concentrations were measured in serum before,
1, 2, 4, 8 and 12 hours after a BID oral application of RAL
with a dosage of 400 mg and 800 mg. Before new mea-
surement after every dose adjustment, a lead-in phase of
more than 24 hours was performed. For optimized reli-
ability, chewed RAL dosage studies were performed semi-
daily at different points of time. At any time, a standard
meal was provided and pantoprazole was co-administered
at a dosage of 40 mg once daily. Usage of pH-altering
agents like pantoprazole was associated with a possible
increase in AUC and Cmax in recent studies [9]. However,
the clinical impact of pH-altering agents and RAL levels
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Methods
RAL levels were measured with high performance liquid
chromatography (HPLC, internal standard: carbamaze-
pine, LLQ 11 ng/ml, validation with Valistat 2.0 program
(Arvecon, Germany)). For statistical analysis, a two-sided
Wilcoxon signed rank test for paired samples was used.
Results
Overall, comparable RAL C2h concentrations were found
with either chewed or swallowed 400 mg or 800 mg of
RAL BID in the case of rifampicin co-administration. Simi-
larly Cmax concentrations were found for 800 mg chewed
and swallowed RAL BID, as well as for 400 mg chewed
and swallowed RAL BID. While Cmax seems to be more
dependent on overall RAL dosing than on swallowed or
chewed tablets, increased AUC12 is clearly linked to higher
RAL dosages per administration. Chewed or swallowed
RAL in a dosage of 800 mg BID led to acceptable AUC12
levels (8767 ng/ml; 10965 ng/ml), whereas 400 mg RAL
BID showed significantly lower AUC12 levels when chewed
or swallowed (3783 ng/ml; 4778 ng/ml). Interestingly,
lower AUC12 levels were seen in chewed dosages of RAL,
compared to a similar dose of swallowed RAL in 400 mg
and 800 mg. For chewed or swallowed 400 mg RAL dos-
ages, a rapid decrease in serum levels was seen, beginning
2–4 hours after application. These findings were confirmed
in low serum levels at the beginning of the next medication
at C0 or C12. Our finding results in dangerously low serum
concentrations 8–12 hours after application of chewed or
swallowed 400 mg RAL BID, as well as in low C0 concen-
trations (<45 ng/ml; 66 ng/ml). Notably lower C0 RAL
levels were also seen for the chewed 800 mg RAL BID dos-
age when compared to the equivalent chewed 800 mg RAL
BID dosage (47 ng/ml). Although a relevant intra-personal
variability in raltegravir serum levels in this HIV-patient
with watery diarrhea and intestinal mal-absorption due to
systemic Mycobacterium avium infection, have to be taken
into account, only swallowed 800 mg RAL led to a
lasting RAL serum concentration of 439 ng/ml at C0
and 885 ng/ml at C12 with acceptable AUC12 of 10965
ng/ml. Pharmacokinetic data in detail are shown in
Table 1, a graph of RAL pharmacokinetics is shown in
Figure 1. However, a comparison of RAL concentra-
tions after chewed and swallowed administration of
RAL showed no statistically significance.
Conclusion
Based on these findings we could not demonstrate opti-
mized RAL levels after taking chewed compared to swal-
lowed RAL tablets in contrast to previously reported
data [5]. Even though there might be changes in RALpharmacokinetics due to pantoprazole co-administration
in our data, we would expect a 3–4 fold higher Cmax and
AUC of RAL levels. It can be speculated that the RAL
levels might be less high as here reported in the absence
of gastric proton pump inhibitors. This might be another
risk factor for lower RAL levels in case of rifampicin co-
administration. Anyhow, whilst potential cost-saving ef-
fects of RAL dosing savings may be important, the risk
of virological failure due to resistance-evolution plays a
crucial role in INI-based antiretroviral therapy. There-
fore, we keep using double-dosed swallowed RAL tablets
in the case of rifampicin co-medicated patients, as recom-
mended by the official prescribing information, until
further data from controlled trials are available. Dose
reduction can cause relevant and potentially dangerous de-
creases in RAL serum levels and AUC12, which can cause
serious harm to HIV-patients. Potential cost-saving effects
should not endanger effective antiretroviral therapy, until
there is further evidence of any other superior strategy.
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